sovutrecdeg   Click here for help

GtoPdb Ligand ID: 14647

Synonyms: CPD-231 [WO2020038415] | TR-231 [WO2020038415]
Compound class: Synthetic organic
Comment: Sovutrecdeg is the INN for a tropomyosin receptor kinase (TRK) degrader, that was included in WHO INN Proposed List 135 (July 2026). Its chemical structure indicates that it is a cereblon (CRBN)-engaging PROTAC degrader, with an entrectinib-derived moiety to bind the target of interest. It is one of the structures claimed in patent WO2020038415A1 (Cullgen Shanghai, company acquired by Gyre Therapeutics in May 2026) [1]. The lead pan-TRK protein degrader being developed by Gyre is CG001419, and although its structure has not been formally disclosed (as of July 2026), sovutrecdeg may be the proposed INN for this clinical candidate.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 15
Hydrogen bond donors 4
Rotatable bonds 12
Topological polar surface area 168.02
Molecular weight 871.93
XLogP 2.71
No. Lipinski's rules broken 3

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CC2=C(C=C1CC3=CC(=CC(=C3)F)F)C(=NN2)NC(=O)C4=CC=C(C=C4NC5CCOCC5)N6CCN(CC6)CC7CN(C7)C8=CC=C9C(=C8)C(=O)N(C%10CCC(=O)NC%10=O)C9=O
Isomeric SMILES C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C=C(C=C3)N4CC(C4)CN5CCN(CC5)C6=CC(=C(C=C6)C(=O)NC7=NNC8=C7C=C(C=C8)CC9=CC(=CC(=C9)F)F)NC%10CCOCC%10
InChI InChI=1S/C47H47F2N9O6/c48-30-18-28(19-31(49)21-30)17-27-1-6-39-38(20-27)43(54-53-39)52-44(60)36-5-3-34(23-40(36)50-32-9-15-64-16-10-32)56-13-11-55(12-14-56)24-29-25-57(26-29)33-2-4-35-37(22-33)47(63)58(46(35)62)41-7-8-42(59)51-45(41)61/h1-6,18-23,29,32,41,50H,7-17,24-26H2,(H,51,59,61)(H2,52,53,54,60)
InChI Key HMQGMDOSEOPTJW-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
CG001419 was progressed as an oncology clinical candidate, in particular for the treatment of solid tumours with oncogenic TRK abnormalities, such as NRTK gene fusions. A second active investigation is CG001419 for pain management.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT07394374 A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities Phase 1/Phase 2 Interventional Cullgen (Shanghai),Inc
NCT06636500 A Phase 1 Study of CG001419 Administered Orally in Healthy Subjects Phase 1 Interventional Cullgen Inc.